Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension

Toshner, Mark; Church, Colin; Harbaum, Lars; J. Rhodes, Christopher; S. Villar Moreschi, Sofia; Liley, James; Jones, R.; Arora, Amit; Batai, Ken; A. Desai, Ankit; Coghlan, Gerry; Simon R. Gibbs, J.; Gor, Dee; Gräf, Stefan; Harlow, Louise; Hernández‐Sánchez, Jules; Howard, Luke; Humbert, Marc; H. Karnes, Jason; G. Kiely, David; A. Kittles, Rick; Knightbridge, Emily; Lam, Brian; A. Lutz, Katie; C. Nichols, William; W. Pauciulo, Michael; Pepke‐Żaba, Joanna; Suntharalingam, Jay; Soubrier, Florent; C. Trembath, Richard; Schwantes‐An, Tae‐Hwi; J. Wort, Stephen; R. Wilkins, Martin; Gaine, Seán; W. Morrell, Nicholas; A. Corris, Paul

doi:10.1183/13993003.02463-2020

Public

Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension

Published in European Respiratory Journal • Sep 29, 2021

Authors:

Mark Toshner

Colin Church

Lars Harbaum

Abstract

Background Inflammation and dysregulated immunity are important in the development of pulmonary arterial hypertension (PAH). Compelling preclinical data supports the therapeutic blockade of interleukin-6 (IL-6) signalling. Methods We conducted a phase 2 open-label study of intravenous tocilizumab (8...

Subject

Medicine

Tocilizumab

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!